STAAR Surgical (NASDAQ:STAA) Director Broadwood Partners, L.P. Purchases 54,764 Shares of Stock

STAAR Surgical Company (NASDAQ:STAA) Director Broadwood Partners, L.P. bought 54,764 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was bought at an average cost of $17.52 per share, with a total value of $959,465.28. Following the transaction, the director directly owned 15,508,393 shares of the company’s stock, valued at approximately $271,707,045.36. This trade represents a 0.35% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, March 13th, Broadwood Partners, L.P. bought 316,017 shares of STAAR Surgical stock. The shares were bought at an average price of $18.61 per share, for a total transaction of $5,881,076.37.
• On Thursday, March 12th, Broadwood Partners, L.P. purchased 299,432 shares of STAAR Surgical stock. The shares were bought at an average cost of $18.12 per share, for a total transaction of $5,425,707.84.
• On Friday, January 9th, Broadwood Partners, L.P. purchased 27,485 shares of STAAR Surgical stock. The shares were bought at an average cost of $22.05 per share, for a total transaction of $606,044.25.
• On Thursday, January 8th, Broadwood Partners, L.P. purchased 3,240 shares of STAAR Surgical stock. The stock was bought at an average price of $21.94 per share, with a total value of $71,085.60.
• On Wednesday, January 7th, Broadwood Partners, L.P. acquired 66,467 shares of STAAR Surgical stock. The stock was purchased at an average cost of $22.00 per share, with a total value of $1,462,274.00.
• On Tuesday, January 6th, Broadwood Partners, L.P. acquired 336,946 shares of STAAR Surgical stock. The shares were purchased at an average price of $21.62 per share, for a total transaction of $7,284,772.52.

STAAR Surgical Trading Up 2.4%

NASDAQ STAA opened at $18.84 on Friday. The stock has a market cap of $932.77 million, a P/E ratio of -11.56 and a beta of 1.05. The company’s fifty day simple moving average is $19.16 and its 200-day simple moving average is $23.71. STAAR Surgical Company has a 52 week low of $14.69 and a 52 week high of $30.81.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings results on Tuesday, March 3rd. The medical instruments supplier reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.51). STAAR Surgical had a negative net margin of 33.60% and a negative return on equity of 10.03%. The firm had revenue of $57.80 million for the quarter, compared to analyst estimates of $75.54 million. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, research analysts expect that STAAR Surgical Company will post -1.14 EPS for the current fiscal year.

Institutional Investors Weigh In On STAAR Surgical

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of STAAR Surgical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after purchasing an additional 1,267 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in STAAR Surgical by 33.4% in the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock worth $9,606,000 after purchasing an additional 136,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in STAAR Surgical by 11.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after buying an additional 12,841 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in STAAR Surgical by 691.0% in the second quarter. PNC Financial Services Group Inc. now owns 3,607 shares of the medical instruments supplier’s stock valued at $61,000 after buying an additional 3,151 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in STAAR Surgical by 0.3% during the second quarter. Geode Capital Management LLC now owns 1,192,821 shares of the medical instruments supplier’s stock valued at $20,018,000 after buying an additional 3,335 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 6th. Jefferies Financial Group reduced their price target on STAAR Surgical from $28.00 to $21.50 and set a “buy” rating for the company in a report on Wednesday, January 28th. Canaccord Genuity Group lowered their price objective on STAAR Surgical from $30.75 to $22.00 and set a “hold” rating for the company in a research note on Thursday, January 15th. BTIG Research restated a “neutral” rating on shares of STAAR Surgical in a report on Tuesday, January 6th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of STAAR Surgical in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $18.94.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.